Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report.
CD4-CD8 ratio
antigens
biomarkers
case reports
combined modality therapy
neoplasm
tumor
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
accepted:
04
08
2020
entrez:
11
9
2020
pubmed:
12
9
2020
medline:
15
10
2021
Statut:
ppublish
Résumé
Combined radioimmunotherapy is currently being investigated to treat patients with cancer. Anti-programmed cell death-1 (PD-1) immunotherapy offers the prospect of long-term disease control in solid tumors. Radiotherapy has the ability to promote immunogenic cell death leading to the release of tumor antigens, increasing infiltration and activation of T cells. New York esophageal squamous cell carcinoma-1 (NY-ESO-1) is a cancer-testis antigen expressed in 20% of advanced gastric cancers and known to induce humoral and cellular immune responses in patients with cancer. We report on the dynamic immune response to the NY-ESO-1 antigen and important immune-related biomarkers in a patient with metastatic gastric cancer treated with radiotherapy combined with anti-PD-1 pembrolizumab antibody.Our patient was an 81-year-old man diagnosed with locally advanced unresectable mismatch repair-deficient gastric cancer having progressed to a metastatic state under a second line of systemic treatment consisting of an anti-PD-1 pembrolizumab antibody. The patient was subsequently treated with local radiotherapy administered concomitantly with anti-PD-1, with a complete response on follow-up radiologic assessment. Disease control was sustained with no further therapy for a period of 12 months before relapse. We have identified an NY-ESO-1-specific interferon-γ (IFN-γ) secretion from the patients' T cells that was significantly increased at response (****p˂0.0001). A novel promiscuous immunogenic NY-ESO-1 peptide P39 (P
Identifiants
pubmed: 32913031
pii: jitc-2020-001278
doi: 10.1136/jitc-2020-001278
pmc: PMC7484873
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : 17118/17
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Mol Immunol. 1997 Feb;34(3):273-81
pubmed: 9224969
PLoS One. 2010 Dec 22;5(12):e15661
pubmed: 21203531
PLoS Comput Biol. 2008 Apr 04;4(4):e1000048
pubmed: 18389056
Cancer Res. 2000 Aug 15;60(16):4499-506
pubmed: 10969798
J Immunol. 2000 Jul 15;165(2):948-55
pubmed: 10878370
World J Otorhinolaryngol Head Neck Surg. 2016 Jul 20;2(2):90-97
pubmed: 29204553
J Hematol Oncol. 2018 Aug 16;11(1):104
pubmed: 30115069
J Immunol. 2009 May 1;182(9):5560-9
pubmed: 19380804
Gastric Cancer. 2009;12(2):95-100
pubmed: 19562463
Cell Mol Life Sci. 2018 Nov;75(22):4151-4162
pubmed: 30173350
Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4760-5
pubmed: 10781081
J Immunol. 2016 Sep 1;197(5):2016-26
pubmed: 27465528
J Immunol. 2005 Feb 1;174(3):1751-9
pubmed: 15661941
Cancer Res. 2012 Oct 15;72(20):5209-18
pubmed: 22915761
Gastric Cancer. 2005;8(2):124-31
pubmed: 15864720
BMC Immunol. 2020 Apr 16;21(1):18
pubmed: 32299365
Hepatogastroenterology. 2001 Jul-Aug;48(40):1199-201
pubmed: 11490833
Immunol Cell Biol. 2006 Jun;84(3):303-17
pubmed: 16681828
Immunity. 2000 May;12(5):495-503
pubmed: 10843382
Cancer Cell Int. 2017 Dec 2;17:114
pubmed: 29213216
Oncoimmunology. 2015 Oct 29;5(3):e1091554
pubmed: 27141352
J Hematol Oncol. 2019 May 31;12(1):54
pubmed: 31151482
PLoS One. 2011;6(11):e28217
pubmed: 22140550
Br J Cancer. 2013 Mar 19;108(5):1119-25
pubmed: 23403818
Trends Cancer. 2016 Jun;2(6):286-294
pubmed: 27774519
BMC Cancer. 2017 May 30;17(1):384
pubmed: 28558708
Gastric Cancer. 2019 Jul;22(4):828-837
pubmed: 30911859
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Cancer Treat Rev. 2018 Feb;63:40-47
pubmed: 29207310
Cell Immunol. 2009;254(2):149-54
pubmed: 18835598
Front Immunol. 2018 Jul 30;9:1769
pubmed: 30108590
Blood. 2009 Aug 6;114(6):1141-9
pubmed: 19470694
J Clin Invest. 2014 Feb;124(2):687-95
pubmed: 24382348
Front Immunol. 2018 May 01;9:947
pubmed: 29770138
Oncotarget. 2015 Jun 30;6(18):15772-87
pubmed: 26158218
Clin Cancer Res. 2009 Sep 1;15(17):5379-88
pubmed: 19706802
Br J Cancer. 2019 Jan;120(1):63-68
pubmed: 30377338
Nature. 2019 Oct;574(7780):696-701
pubmed: 31645760
J Transl Med. 2019 Apr 11;17(1):120
pubmed: 30971280
Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16723-8
pubmed: 21933959
Clin Cancer Res. 2016 Jan 1;22(1):20-5
pubmed: 26362999
Front Oncol. 2019 Mar 19;9:163
pubmed: 30941312
Immunity. 2009 Nov 20;31(5):787-98
pubmed: 19879162
Acta Oncol. 1994;33(2):187-90
pubmed: 8204274
Nat Biomed Eng. 2018 Aug;2(8):600-610
pubmed: 31015630
J Transl Med. 2020 Mar 27;18(1):140
pubmed: 32220256
Nat Commun. 2017 Nov 10;8(1):1404
pubmed: 29123081
Infect Immun. 2007 Sep;75(9):4357-63
pubmed: 17562763
J Exp Med. 2009 Dec 21;206(13):3015-29
pubmed: 20008522
Aging (Albany NY). 2020 Mar 24;12(6):4879-4895
pubmed: 32208363
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
J Immunother Cancer. 2019 Feb 11;7(1):42
pubmed: 30744691
J Exp Med. 2006 May 15;203(5):1259-71
pubmed: 16636135
Nat Rev Cancer. 2009 May;9(5):361-71
pubmed: 19343034
Gastric Cancer. 2020 Sep;23(5):893-903
pubmed: 32180056